Hemolysis as Expression of Nanoparticles-Induced Cytotoxicity in Red Blood Cells

Please download to get full document.

View again

of 6
All materials on our website are shared by users. If you have any questions about copyright issues, please report us to resolve them. We are always happy to assist you.
Information Report
Category:

Science & Technology

Published:

Views: 0 | Pages: 6

Extension: PDF | Download: 0

Share
Related documents
Description
Hemolysis as Expression of Nanoparticles-Induced Cytotoxicity in Red Blood Cells Teodora Mocan, MD, PhD, Abstract Nanomedicine has a huge potential to bring benefits in prophylaxis, diagnosis and treatment
Transcript
Hemolysis as Expression of Nanoparticles-Induced Cytotoxicity in Red Blood Cells Teodora Mocan, MD, PhD, Abstract Nanomedicine has a huge potential to bring benefits in prophylaxis, diagnosis and treatment of various diseases, with increased socio-economic benefits. Since most of the future applications of therapeutic nanoparticles (NPs) are based on intravenous/oral administration, experiments on their interaction with human blood components are of extreme importance. In this context, the knowledge of the degree to which damage on red blood cells following exposure to silver nanoparticles contributes to the overall toxicity of various NPs is still highly needed. The present paper unprecedentedly assesses the hemolytic impact of biomedical nanoparticles on red blood cells (RBCs). animal models, including zebrafish[13], Sprague-Dawley rats[14-17], mice[18] showed an increased level of toxicity of these nanoparticles. Following administration, the transit of these nanoparticles through the blood flow constantly occurs independent of administration route.[14-19] Since most of the future applications of therapeutic nanoparticles are based on intravenous/oral administration, experiments on their interaction with human blood components are of extreme importance. In this context, the knowledge of the degree to which damage on red blood cells following exposure to silver nanoparticles contributes to the overall toxicity of various Nps is still highly needed. The present paper unprecedentedly assesses the hemolytic impact of biomedical nanoparticles on red blood cells. (RBCs) Keywords cytotoxicity, hemolysis, nanoparticles, erythrocyte, therapy N I. INTRODUCTION anotechnology implies the development of materials and functional structures with at least one characteristic nanometric dimension. Biomedical nanoparticles have interesting electronic properties, based on the unique size-dependent features thus exhibiting highly photothermal effect with surface plasmon resonance and strong optical absorption.[1-4] Their unique chemical stability make these materials suitable for the attachment of biomolecules like peptides, pharmacologically active substances and genes. So far, these nanoparticles have proven several promising effects, such as antitumor[5] gene therapy vector[6], anti-inflammatory[7], antiviral[8] and antibacterial effects[9, 10]. Even though most literature data dedicated to therapeutic nanoparticles refer to in vitro toxicological assessments[11, 12], recent data brings evidences on their in vivo toxicity. Various This work was funded by the Romanian Ministry of Education and Research (PN-II-PT-PCCA , PN-II-RU-TE ; PN-II-RU -PD PN-II-PT-PCCA ; PN-II-PT -PCCA ). Department of Physiology, Iuliu Hatieganu University of Medicine and Pharmacy, Victor Babes nr.8, Cluj-Napoca, Romania. *Correspondence to Teodora Mocan ( 7 II. HEMOLYSIS RBC lysis has been demonstrated for amorphous nanomaterials such as silica NPs, thus limiting their rapid application into human trials. The incriminated mechanisms is centered on silanol groups existent on the outer surface of NPs.[20] Also, tricalcium phosphate (TCP) and Hydroxyapatite (HAP) nanoparticles (NPs), highly used in various medical applications, have been proven to increase the hemolysis rate with more than 5 % at 1000µg/ml concentration of RBC exposure. The two types of nanoparticles revealed different outcome, with higher hemolytic effect following TCP exposure. The effect on RBC is accompanied by of reduction in macrophages proliferation rate.[21] This is not the only report on HAP nanoparticles to produce hemolysis. Another research team selected HAP-NPs ranging from 30 to 80 nm in diameter. Direct contact exposure as well as agar overlay techniques were used to analyze cytotoxicity on rat macrophages. Also, hemolysis test was used to assess effects of NPs exposure on RBC.HSP70 identification by means of Western Blot was also performed. Similar to other studies, an increase of over 5% in hemolysis rate was found for concentrations of over 1000 µg/ml. HSP7 was up-regulated by concentrations of 100 µg/ml HAP NPs and inhibition of macrophages proliferation could be found at concentrations as low as 20 µg/ml. The study draws a signal of concern regarding the opportunity of selecting HAP NPs for medical applications.[22] Another interesting study focused on the cytotoxic effects of silver powders with different particulate diameter. Two micron-sized and two nano-sized powders were prepared for testing by water dispersion, followed by complete characterization of obtained solution (SERS, TEM, and DLS). Although two distinct methods were used for preparation of solution needed for particle-rbc contact, nano-sized silver particles revealed significantly higher hemolytic rates compared to micro-sized silver particles are similar concentration (220 μg/ml) regardless the method used. According to presented data, this could be due to several factors, including: increased silver ion release, increased surface area or mechanical interaction with RBC. [23]. Similar data have been reported by another group who showed a decreasing hemolysis rate with increasing NP size for silver NPs exposure. The authors incriminate, similar to other researchers, higher effective surface with consecutive higher silver ions release in smaller particulate size as compared to larger ones.[24] In all this cases the hemolytic effect was considered to be induced by the release of oxidative stress products following exposure. (Figure 1) Fig. 1. Schematic illustration of oxidative stress induced mechanisms of hemolysis following administration of various nanoparticles. Comparison between the observed effects following RBC exposure to different types of nanoparticles has been proposed by other studies. One of them focused on hemolysis, erythrocyte sedimentation rate, membrane topography, hemagglutination, and lipid peroxidation induces by three distinct types of NPs: silver, gold and platinum following their contact with RBC. Similar to the results presented, data suggested silver NPs to be less hemocompatible as compared to platinum and gold NPs. Following silver NPs exposure at 100 µg ml 1, evidences of hemolysis, membrane damage, morphological alterations, and hemagglutination as well as cytoskeleton changes were recorded. Also, RBC membrane presented multiple depressions and pits following exposure. None of these noxious effects were recorded following macro-silver exposure. Interestingly, DNA alterations have been recorded in nucleated cells as a result of their exposure to hemolyzed erythrocyte fraction.[25] The hemolytic and antimicrobial properties of silver nanoparticles and silver ions (I) combined with various antimicrobial agents, including polymimyxin B were tested. The antimicrobial activity against Gram negative bacteria has demonstrated to act as an additive effect of both materials and antimicrobial agents. Moreover, a very low hemolytic activity of silver nanoparticles has been reported as compared to AgNO3. The authors therefore conclude that synergic treatment using the combined effect of 8 both polymyxin B and silver NPs represent a promising antimicrobial treatment against Gram-negative bacteria.[26] Other researchers have focused on nanomaterials like iron oxide (Fe2O3) and zinc oxide (ZnO) as well as multi-walled carbon nanotubes (MWCNTs) and their effect on RBC. Possible effect modulation induced by their shape and composition has also being studied. Results revealed extended hemolysis for MWCNTs as well as absence of hemagglutination following RBC exposure. This conclusion was sustained by AFM images showing no signs of larger particles formation due to RBC agglomeration. Based on the already known biocompatibility of macro-carbon materials, investigators draw the conclusion that the effects are due to the shape alone and not the composition of the NPs. For iron oxide NPs, results revealed an increased NP-RBC binding, and a weak tendency of the NPs themselves to form large aggregates. By contrast, zinc oxide NPs recorded high rate of clumping. Such large, micrometer-sized aggregates formed by zinc oxide NPs are very mobile within blood flow and become very toxic to RBCs. Nanosilica NPs, following aggregate formation, has been also said to promote hemolysis. The process follows various steps including shape change from discocytes to spherocytes, loss of membrane s resiliency and flexibility, swelling and volume increase and finally membrane break.[27] Also, it has been demonstrated that silicon dioxide (SiO2) NPs are able to induce a higher the 5% hemolysis rate following in vivo continuous injection exposure.[28] Comparison between different silica NPs has also been investigated. It has been shown that amorphous silica is able to induce a significantly higher hemolysis rate as compared to MCM-41-type mesoporous silica NPs, thus making the latter a promising candidate for in vivo applications.[29] Research focusing on TiO2 NPs has brought evidences of negative effects such as hemolysis (in a dose-dependent manner), sedimentation rate, or hemagglutination. The process is, most probably, passing, similar to other particles through several starting with RBC attachment, TiO2 NPs trans-membrane transport and oxidative stress and ending with membrane breakage.[30] Lipid-based nanoparticles with crystalline structure (LCNPs) have also been intensely investigated. Different chemical compositions have been tested for their safety as potential intravenous drugs components. Results showed an intense hemolytic effect for glycerol monooleate (GMO)-based LCNPs, thus making such structures incompatible for human intravenous administration. No hemolysis was observed in the case of soy phosphatidylcholine (SPC)/GDO, making them an appropriate candidate for various applications. Also, intermediate hemolysis rate for as long chained molecules, such as sponge phase nanoparticles based on DGMO/GDO/polysorbate 80 (P80). Such molecules should be used with caution in application heading in vivo intravenous administration. All data, however, converge to the conclusion that hemolytic properties of LCNPs are strongly connected to the chemical structure of the monomers in the case [31]. Similar data have been obtained in the case of partially quaternized poly [thio-1-(n,n-diethyl-aminomethyl) ethylene]s, Q-P(T DAE) NPs. The nanostructures have been demonstrated to induce RBC lipid bilayer disruption with hemolysis, electrostatic attraction followed by hemagglutination. Also, effects have demonstrated to be dependent on blood protein content.[32] A group of researchers focused on synthesis and characterization of surface-modified SLN for adsorptive protein loading. Both the modulation of the emulsifier concentration and the lipid matrix have been performed. As demonstrated by complex techniques, such as X ray diffraction, thermoanalysis, electron microscopy demonstrated the formation of crystalline and anisometrical particles. Hemolysis test, performed as a measure of toxicity revealed safe rates of RBC lysis of under 5 % (1.1 to 4.6%).[33] Microemulsion-based nanoparticles (MEs) has been proposed for in vivo applications. Various toxicological data have been reported. At similar pharmacological concentrations sodium caprylate induced significant hemolysis while MEs and pluronic surfactants seem biocompatible.[34] Other types of nanoparticles, like for example E78NPs were found to absolutely harmless to RBC membrane integrity, especially at low concentrations (1mg/mL), thus making the suitable for blood-delivered applications regardless the surface alteration (PEG-coated or non-pegylated E78 NPs).[35] Similarly, de novo synthesized NPs, such as heparin-immobilized polyethersulfone (PES) has passed hemolysis test, demonstrating RBC lysis of less than 5%.[36] Likewise, a study testing the effect of RBC exposure to calix-arene based Solid Lipid Nanoparticles (SLNs) demonstrated no hemolytic effect.[37] Crystalline carbon nanoparticles(cnps) with intense fluorescent properties obtained by means of addition of different organic tags, such as α-naphthylamine, fluorescein and rhodamine B. were synthesized. Erythrocyte exposure to these type of nanoparticles induced no signs of toxicity.[38] Minimal cytotoxicity and RBC toxicity was observed for polymethacrylate nanoparticles (NP), a type of NPs designed for applications of oligodeoxynucleotides delivery.[39] Cross-linked gelatin nanoparticles with the encapsulation of cycloheximine, an already demonstrated inhibitor for protein synthesis have also been designed. Data obtained from blood compatibility testing experiments revealed minimal or no signs of hemolysis.[40] An increasing interest has been generated by layered double hydroxides (LDHs) for cell delivery of bio-active molecules, drugs and genes. However, only limited studies have focused on testing their biocompatibility testing. One of these studies tested several chemical compositions (MgAl-LDH as well as ZnAl-LDL). In vitro testing was performed on carcinoma cells, normal human cells and RBCs. Quantification of possible noxious effects was done by measuring cell proliferation, membrane damage, cell proliferation and hemolytic effect. None of the tested chemical structures was able to induce significant hemolysis. A slightly higher toxicity was recorded for ZnAl-LDH as compared to MgAl-LDH, detectable as increased hemolysis and membrane damage. The authors conclude that LDH could represent a promising substrate for future in vivo drug delivery applications.[41] By means of emulsion/solvent evaporation 9 technique, a study imagined the method to generate a distinct type of NPs, made of a conjugate of poly(d,l-lactide-co-glycolide) with alendronate (PLGA ALE NPs). Following administration, lysis of erythrocytes was studied. No hemolysis was detected following PLGA ALE NPs exposure, the rate being similar to that recorded for PBS exposure.[42] Another research group studied nanoparticles based on complex polymeric structures, such as poly(3-hydroxybutyrate) poly(ethylene glycol) poly(3- hydroxyl butyrate) (PHB-PEG-PHB). They have been proposed for drug delivery applications, therefore cytotoxicity and hemolysis test were performed. No signs of cytotoxicity and hemotoxicity were recorded, even for concentrations as high as 120μg/mL. These results sustain the designed NPs potential for the intended applications.[43] Other types of NPs, like N-acyl chitosan nanoparticles, prepared by the tripolyphosphate anions reactions, have been designed and proposed for several applications. The testing experiments revealed good hemocompatibility, as quantified by thromboelastography and hemolysis.[44] It has been already known that cytostatic therapies have hematological toxicity as a common adverse effect. Various methods have been proposed for diminishing these effects. One of them was to encapsulate the drug into biocompatible materials. One such treatment agent is Paclitaxel, a drug known to present a low stability in aqueous media and to present various adverse effects induced by the solubilizer used in preparation. One group of researchers developed a new formulation of amphiphilic cyclodextrin nanoparticles by encapsulation of Paclitaxel. Hemolysis and cytotoxicity experiments were performed to test the biocompatibility of the newly synthesized NPs. Data were compared to a common vehicle: cremophor: ethanol (50:50 v/v). Significantly reduced hemolysis was obtained for the encapsulated nanoparticles, as it could be inferred by SEM- imaging.[45] Another cytostatic agent of interest was Doxorubicin. For the encapsulation purpose, spherical self-assembled nanoparticles based on oleoyl-chitosan (OCH) have been developed. The efficiency of Doxorubicin loading was 52.6%. Drug releasing was complete and rapid at PH =3.8. At PH 7.4 releasing process had two distinct phases: a first burst release, followed by a sustained release. Drug efficiency, quantified by the death rates following in vitro exposure of various cancer cell lines, was significantly higher than Doxorubicin solution alone. However, before proposing any particular applications, the newly synthesized NPs have been tested by means of MTT assay and hemolysis test. No cytotoxicity signs were found on embryo fibroblasts. All hemolysis experiments, performed under distinct conditions resulted in acceptable hemolysis rates (under 5%). All data suggest a good potential for the developed NPs towards human anticancer applications.[46] Similarly, self-assembled Fe3O4 magnetic nanoparticles (MNPs) were developed for encapsulation of daunorubicin (DNR). By contrast with DNR alone, the so-loaded capsule presented a good hemocompatibility, with no hemolysis.[47] Similarly, research has been developed for reducing the hemotoxicity of camptothecin, a potent anticancer drug. Lipid nanoparticles based on different lipid cores were designed for its encapsulation. The final NPs, holding camptothecin content revealed a hemolysis rate of under 5%, thus placing the RBC adverse reaction within acceptable limits.[48] Not only the cytostatic agents raised the interest of researchers for encapsulation. Anti-malarial drugs, such as arthemeter (ARM) were loaded in lipid mass. For this purpose, a film of thin-film hydration method was used. The lipid structures were glyceryl soybean oil and trimyristate (solid lipid). Particles were further loaded with the ARM 10%. Nanoparticulate surface was optimized by means of non-ionic, cationic and anionic surfactants. Testing of the newly developed NPs revealed a level of hemolysis of under 7% and a significantly enhanced in vivo anti-malarial activity as compared to the regular drug solution, currently on the market.[49] Interesting results were brought by experiments testing NPs of mixed chemical structure. High biocompatibility, including low hemolytic rates were found for monodisperse Au-silicate nanoparticles (10.7 ± 1.6 nm in diameter).[50] Similar data have been reported following RBC exposure to core shell Au composite magnetic nanoparticles (MNPs). All concentrations used induces hemolysis rates of under 5%[51], the already established cut-off for hemolytic effect.[52] Also, a complex method has been imagined for superparamagnetic Fe3O4nanoparticles synthesis using nickel-nitrilotriacetate (Ni-NTA) structure modification. The opportunity of their application for vivo imaging has been demonstrated by the lack of hemolysis after RBC exposure.[53] A very recent report demonstrates the modulation of hemolytic properties of nanoparticles by the protein content of plasma. Data shown demonstrate that RBCs exposure to polystyrene nanoparticles (PS-NP) in protein-free medium results in hemolysis (in a particle). It has also been reported that PH can represent another modulator factor for the hemolytic process. The authors focused on protein-encapsulated hydrophobic γ-pga (γ-hpga) nanoparticles. Due to a conformational change of γ-hpga NPs, hemolysis appears under PH conditions ranging from 7 downward to 5.5, but never at physiological PH. Hydrophobicity, increased by the PH-induced conformational change, might be the mechanism responsible for membrane disruption. The authors conclude that the designed NPs could find their utility into DNA, protein, drug delivery or other systems based on endosome-disruptive NPs.[54] These findings generated the idea to reduce the hemolysis rate by different methods. One of them consists of using special types of nanoparticles (such as magnet-controlled sorbent NPs: MCS-B) for extracorporeal processing of blood. A group of researchers performed complex experiments towards three different aims. The first one was to detect the existence of a relationship between the timing of hemolysis process debut and the intensity of MCS-B exposure. The second objective was to investigate specific metabolic pathways in exposed RBC: ATP trans
Recommended
View more...
We Need Your Support
Thank you for visiting our website and your interest in our free products and services. We are nonprofit website to share and download documents. To the running of this website, we need your help to support us.

Thanks to everyone for your continued support.

No, Thanks
SAVE OUR EARTH

We need your sign to support Project to invent "SMART AND CONTROLLABLE REFLECTIVE BALLOONS" to cover the Sun and Save Our Earth.

More details...

Sign Now!

We are very appreciated for your Prompt Action!

x